CANTEL MEDICAL CORP. (NYSE:CMD) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers

On November 1, 2017, the Board of Directors of Cantel Medical Corp. (the “Company”) appointed Dr. Peter Pronovost (age 52) as a member of the Board to fill a newly created position after expanding the Board from nine members to ten members.

Dr. Pronovost is a professor of anesthesiology and critical care medicine, surgery, nursing, health policy and management, engineering, and business at the Johns Hopkins University School of Medicine. He is a practicing critical care physician who is dedicated to finding ways to make hospitals and healthcare safer for patients. In June 2011, he was named director of the new Armstrong Institute for Patient Safety and Quality at Johns Hopkins, as well as Johns Hopkins Medicine’s senior vice president for patient safety and quality. Dr. Pronovost is also a member of the Institute of Medicine-National Academy of Science. In 2008 he was named one of Time magazine’s 100 most influential people in the world for his work in improving healthcare safety. He is a lecturer and author in the fields of patient safety and healthcare management. Additionally, Dr. Pronovost is a researcher centered on improving the quality of care. Previously, from January 2010 to June 2015, Dr. Pronovost served as a director of the Company.

Dr. Pronovost will be eligible for annual awards of restricted stock units under the Company’s 2016 Equity Incentive Plan, as well as director’s fees, on the same terms as the Company’s other non-employee directors (as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 28, 2016), except that for the fiscal year ending July 31, 2018 he will receive a pro rata portion of the annual retainer based on the number of months in which he serves as a director during such fiscal year.

There is no arrangement or understanding between Dr. Pronovost and any other person to which he was selected as a director. There are no transactions, relationships or agreements between Dr. Pronovost and the Company that would require disclosure to Item 404(a)of Regulation S-K.

Dr. Pronovost will serve on the Nominating and Governance Committee of the Board of Directors.

About CANTEL MEDICAL CORP. (NYSE:CMD)

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies. The Company’s Water Purification and Filtration segment includes water purification equipment and services, filtration and separation products, and disinfectant, sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use, infection prevention and control healthcare products. The Company’s Dialysis segment includes medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates and other supplies for renal dialysis. The Company offers a range of filters utilizing hollow fiber membrane technology.